Sirio Pharma (300791) - Total Assets
Based on the latest financial reports, Sirio Pharma (300791) holds total assets worth CN¥5.74 Billion CNY (≈ $839.26 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 300791 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Sirio Pharma - Total Assets Trend (2016–2024)
This chart illustrates how Sirio Pharma's total assets have evolved over time, based on quarterly financial data. Check Sirio Pharma (300791) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Sirio Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Sirio Pharma's total assets of CN¥5.74 Billion consist of 36.9% current assets and 63.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.6% |
| Accounts Receivable | CN¥675.01 Million | 12.3% |
| Inventory | CN¥481.66 Million | 8.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥558.27 Million | 10.2% |
| Goodwill | CN¥417.10 Million | 7.6% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sirio Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Sirio Pharma (300791) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sirio Pharma's current assets represent 36.9% of total assets in 2024, a decrease from 56.1% in 2016.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2024, down from 18.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, a decrease from 22.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 12.3% of total assets.
Sirio Pharma Competitors by Total Assets
Key competitors of Sirio Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nestle S.A.
SW:NESN
|
Switzerland | CHF127.15 Billion |
|
Foshan Haitian Flavouring and Food Co Ltd
SHG:603288
|
China | CN¥48.38 Billion |
|
Lotus Bakeries
BR:LOTB
|
Belgium | €1.54 Billion |
|
The Magnum Ice Cream Company N.V.
AS:MICC
|
Netherlands | €7.49 Billion |
|
AAK AB
ST:AAK
|
Sweden | Skr32.62 Billion |
|
PT Indofood Sukses Makmur Tbk
JK:INDF
|
Indonesia | Rp226.51 Trillion |
|
Tiger Brands Ltd
JSE:TBS
|
South Africa | ZAC26.95 Billion |
|
Greencore Group plc
F:GCG
|
Germany | €1.27 Billion |
Sirio Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 2.49 | 3.64 |
| Quick Ratio | 1.37 | 1.76 | 2.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥959.34 Million | CN¥1.12 Billion | CN¥1.10 Billion |
Sirio Pharma - Advanced Valuation Insights
This section examines the relationship between Sirio Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | CN¥5.49 Billion |
| Market Capitalization | $751.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sirio Pharma's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Sirio Pharma's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Sirio Pharma (2016–2024)
The table below shows the annual total assets of Sirio Pharma from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.49 Billion ≈ $802.78 Million |
+5.59% |
| 2023-12-31 | CN¥5.20 Billion ≈ $760.30 Million |
+24.13% |
| 2022-12-31 | CN¥4.19 Billion ≈ $612.52 Million |
+9.57% |
| 2021-12-31 | CN¥3.82 Billion ≈ $559.00 Million |
+44.17% |
| 2020-12-31 | CN¥2.65 Billion ≈ $387.73 Million |
+12.32% |
| 2019-12-31 | CN¥2.36 Billion ≈ $345.20 Million |
+52.83% |
| 2018-12-31 | CN¥1.54 Billion ≈ $225.87 Million |
+19.86% |
| 2017-12-31 | CN¥1.29 Billion ≈ $188.44 Million |
-11.92% |
| 2016-12-31 | CN¥1.46 Billion ≈ $213.93 Million |
-- |
About Sirio Pharma
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. … Read more